CL2025002772A1 - Anticuerpos anti-gpvi y fragmentos funcionales de los mismos - Google Patents

Anticuerpos anti-gpvi y fragmentos funcionales de los mismos

Info

Publication number
CL2025002772A1
CL2025002772A1 CL2025002772A CL2025002772A CL2025002772A1 CL 2025002772 A1 CL2025002772 A1 CL 2025002772A1 CL 2025002772 A CL2025002772 A CL 2025002772A CL 2025002772 A CL2025002772 A CL 2025002772A CL 2025002772 A1 CL2025002772 A1 CL 2025002772A1
Authority
CL
Chile
Prior art keywords
functional fragments
gpvi antibodies
gpvi
antibodies
binding
Prior art date
Application number
CL2025002772A
Other languages
English (en)
Inventor
Nieswandt Bernhard
Original Assignee
Emfret Analytics Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emfret Analytics Gmbh & Co Kg filed Critical Emfret Analytics Gmbh & Co Kg
Publication of CL2025002772A1 publication Critical patent/CL2025002772A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a moléculas de anticuerpos y fragmentos funcionales de las mismas, capaces de unirse a la glicoproteína VI humana (GPVI), a procedimientos para su producción y a sus usos terapéuticos.
CL2025002772A 2023-03-16 2025-09-12 Anticuerpos anti-gpvi y fragmentos funcionales de los mismos CL2025002772A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP23162489.1A EP4431526A1 (en) 2023-03-16 2023-03-16 Anti-gpvi antibodies and functional fragments thereof

Publications (1)

Publication Number Publication Date
CL2025002772A1 true CL2025002772A1 (es) 2025-11-28

Family

ID=85703579

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025002772A CL2025002772A1 (es) 2023-03-16 2025-09-12 Anticuerpos anti-gpvi y fragmentos funcionales de los mismos

Country Status (9)

Country Link
EP (2) EP4431526A1 (es)
JP (1) JP2026509897A (es)
KR (1) KR20250158023A (es)
CN (1) CN121127495A (es)
AU (1) AU2024236033A1 (es)
CL (1) CL2025002772A1 (es)
IL (1) IL323344A (es)
MX (1) MX2025010882A (es)
WO (1) WO2024189203A1 (es)

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
EP1224942A1 (en) 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
KR101194446B1 (ko) 2004-04-29 2012-10-24 오쓰까 세이야꾸 가부시키가이샤 당단백 ｖｉ에 특이적인 항체 및 그의 제조방법
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2006017910A2 (en) 2004-08-20 2006-02-23 Track 'n' Find Pty Ltd Device for assisting in finding an article using fluorescence
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
EP1876240B1 (en) 2005-04-28 2012-08-22 Mochida Pharmaceutical Co., Ltd. Anti-human platelet membrane glycoprotein vi monoclonal antibody
EP1916259A1 (en) 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
PT2513147T (pt) 2009-12-18 2016-10-11 Sanofi Sa Novos anticorpos antagonistas e seus fragmentos fab contra gpvi e utilizações destes
HRP20220910T1 (hr) 2015-08-05 2022-10-28 Acticor Biotech Nova anti-humana gpvi antitijela i njihove uporabe
EP3424957A1 (en) 2017-07-03 2019-01-09 advanceCOR GmbH Fusion protein

Also Published As

Publication number Publication date
WO2024189203A1 (en) 2024-09-19
EP4431526A1 (en) 2024-09-18
JP2026509897A (ja) 2026-03-25
EP4680637A1 (en) 2026-01-21
AU2024236033A1 (en) 2025-09-25
KR20250158023A (ko) 2025-11-05
IL323344A (en) 2025-11-01
MX2025010882A (es) 2025-10-01
CN121127495A (zh) 2025-12-12

Similar Documents

Publication Publication Date Title
MX2021007290A (es) Anticuerpo humanizado anti-pd-1 humana.
CL2023003607A1 (es) Anticuerpos anti-ccr8 y usos de los mismos
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
CL2024001473A1 (es) Conjugados de fármacos y anticuerpos anti-ccr7
MX2025000370A (es) Anticuerpos anti-ctla4 y metodos para elaborarlos y usarlos
AR122833A2 (es) Anticuerpos que se unen a il-4 y/o il-13 y sus usos
CL2019000836A1 (es) Construcciones de inmunoglobulina heterodiméricas y métodos de preparación de las mismas.
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
MX2020011914A (es) Anticuerpos anti-dll3 y usos de los mismos.
CO2019009815A2 (es) Combinaciones farmacéuticas
ECSP23025680A (es) Moléculas de unión a b7-h4 terapéuticas
CL2025002941A1 (es) Anticuerpos anti-sirp-alfa.
CO2022015202A2 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
CO2020014663A2 (es) Anticuerpo de repetición de dipéptidos (dpr) anti (poli-ga) derivado de humanos
BR112022023697A2 (pt) Métodos e meios para a produção de moléculas semelhantes a ig
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2024015285A (es) Anticuerpos anti-egfr/met y usos de los mismos
CL2022001120A1 (es) Anticuerpos anti inmunorreceptor de células t con dominios de inmunoglobulina y motivo inhibidor basado en tirosina de inmunorreceptor (tigit) y sus usos
ECSP21082527A (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
ECSP23078844A (es) Moléculas de unión terapéuticas
CL2025000292A1 (es) Anticuerpos tmem219 y usos terapéuticos de los mismos
CL2023000442A1 (es) Anticuerpos y fragmentos de unión a antígeno específicos para fcer1a, y sus usos
UY39699A (es) Anticuerpos anti-tau y usos de estos
CL2025002772A1 (es) Anticuerpos anti-gpvi y fragmentos funcionales de los mismos
CO2023015859A2 (es) Anticuerpos para tratar alfa-sinucleinopatías